文章核心观点 - 文章未提供关于具体公司或行业的实质性新闻内容、事件、财报数据或分析观点 [1][2] 根据相关目录分别进行总结 - 文章内容仅包含分析师及发布平台的标准披露声明 未涉及任何具体的行业趋势、公司动态、财务数据或投资分析 [1][2]

After two pieces in the second half of the year, it's fair to say the ' Pizookie Dip ' didn't take long to show its face.I’m an equity analyst and founder of Goulart’s Restaurant Stocks, a research firm focused on the U.S. restaurant industry — from quick-service and fast casual to fine dining and niche concepts. I lead all thematic research and valuation efforts, applying advanced financial modeling, sector-specific KPIs, and strategic insights to uncover hidden value across public equities. In addition to ...

To ensure this doesn't happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

It has been a while since I last reviewed Alphabet (NASDAQ: GOOG / GOOGL ) and stamped it with a Buy rating back in April . It is fair to say that the companyAs a detail-oriented investor with a strong foundation in finance and business writing, I focus on analyzing undervalued and disliked companies or industries that have strong fundamentals and good cash flows. I have a particular interest in sectors such as Oil&Gas and consumer goods. Basically, anything that has been unloved for unjustified reasons tha ...

The April thesis on First Solar, Inc. ( FSLR ) has played out earlier and better than I expected. The price target of $200 has been outrun in just over 7 months, helped somewhat by an overallI am a stock analyst with over 20 years of experience in quantitative research, financial modeling, and risk management. My focus is on equity valuation, market trends, and portfolio optimization to uncover high-growth investment opportunities. As a former Vice President at Barclays, I led teams in model validation, str ...

It has been a while since I last reviewed Alphabet (NASDAQ: GOOG / GOOGL ) and stamped it with a Buy rating back in April . It is fair to say that the companyAs a detail-oriented investor with a strong foundation in finance and business writing, I focus on analyzing undervalued and disliked companies or industries that have strong fundamentals and good cash flows. I have a particular interest in sectors such as Oil&Gas and consumer goods. Basically, anything that has been unloved for unjustified reasons tha ...

Analyst's Disclosure:I/we have a beneficial long position in the shares of GBDC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I'm a retail investor based in Sydney with three years of experience focusing on achieving financial independence through strategic investments ...

While everyone focuses on the billions of dollars being spent on purchasing GPUs and building AI infrastructure, Oracle’s ( ORCL ) edge in data software appears to be largely ignored by the market. I had alsoAs an Investment Research Analyst, I cover publicly listed securities (stocks and funds) listed on the NYSE/NASDAQ and mostly covering tech. My insights are mostly based on my own experience investing for 25 years, together with qualifications in Business Management and Equity Finance.I also have a degr ...

My assessment of Arcellx ( ACLX ) leads me to a very optimistic conclusion: This is not simply one more CAR T firm competing in the multiple myeloma space. In my opinion, Arcellx is creating a commercially viable, scalable, andI have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologies and forward-thinking enterprises. My approach is a mix of fundamental analysis and future ...

Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure:I/we ...